Metacognition deficits as a risk factor for prospective motivation deficits in schizophrenia spectrum disorders

Lauren Luther, Ruth L. Firmin, Kyle S. Minor, Jenifer Vohs, Benjamin Buck, Kelly D. Buck, Paul H. Lysaker

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Although motivation deficits are key determinants of functional outcomes, little is known about factors that contribute to prospective motivation in people with schizophrenia. One candidate factor is metacognition, or the ability to form complex representations about oneself, others, and the world. This study aimed to assess whether metacognition deficits were a significant predictor of reduced prospective motivation, after controlling for the effects of baseline motivation, anticipatory pleasure, and antipsychotic medication dose. Fifty-one participants with a schizophrenia spectrum disorder completed measures of metacognition and anticipatory pleasure at baseline; participants also completed a measure of motivation at baseline and six months after the initial assessment. Baseline antipsychotic dose was obtained from medical charts. Hierarchical regression analysis revealed that lower levels of baseline metacognition significantly predicted reduced levels of motivation assessed six months later, after controlling for baseline levels of motivation, anticipatory pleasure, and antipsychotic dose. Higher baseline antipsychotic dose was also a significant predictor of reduced six month motivation. Results suggest that metacognition deficits and higher antipsychotic dose may be risk factors for the development of motivation deficits in schizophrenia. Implications include utilizing interventions to improve metacognition in conjunction with evaluating and possibly lowering antipsychotic dose for people struggling with motivation deficits.

Original languageEnglish (US)
Pages (from-to)172-178
Number of pages7
JournalPsychiatry Research
Volume245
DOIs
StatePublished - Nov 30 2016

Fingerprint

Motivation
Schizophrenia
Antipsychotic Agents
Pleasure
Metacognition
Aptitude
Regression Analysis

Keywords

  • Anticipatory pleasure
  • Antipsychotic medication
  • Metacognition
  • Motivation
  • Schizophrenia

ASJC Scopus subject areas

  • Medicine(all)
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Metacognition deficits as a risk factor for prospective motivation deficits in schizophrenia spectrum disorders. / Luther, Lauren; Firmin, Ruth L.; Minor, Kyle S.; Vohs, Jenifer; Buck, Benjamin; Buck, Kelly D.; Lysaker, Paul H.

In: Psychiatry Research, Vol. 245, 30.11.2016, p. 172-178.

Research output: Contribution to journalArticle

Luther, Lauren ; Firmin, Ruth L. ; Minor, Kyle S. ; Vohs, Jenifer ; Buck, Benjamin ; Buck, Kelly D. ; Lysaker, Paul H. / Metacognition deficits as a risk factor for prospective motivation deficits in schizophrenia spectrum disorders. In: Psychiatry Research. 2016 ; Vol. 245. pp. 172-178.
@article{36388086635342baa3d159cb60e6ca9a,
title = "Metacognition deficits as a risk factor for prospective motivation deficits in schizophrenia spectrum disorders",
abstract = "Although motivation deficits are key determinants of functional outcomes, little is known about factors that contribute to prospective motivation in people with schizophrenia. One candidate factor is metacognition, or the ability to form complex representations about oneself, others, and the world. This study aimed to assess whether metacognition deficits were a significant predictor of reduced prospective motivation, after controlling for the effects of baseline motivation, anticipatory pleasure, and antipsychotic medication dose. Fifty-one participants with a schizophrenia spectrum disorder completed measures of metacognition and anticipatory pleasure at baseline; participants also completed a measure of motivation at baseline and six months after the initial assessment. Baseline antipsychotic dose was obtained from medical charts. Hierarchical regression analysis revealed that lower levels of baseline metacognition significantly predicted reduced levels of motivation assessed six months later, after controlling for baseline levels of motivation, anticipatory pleasure, and antipsychotic dose. Higher baseline antipsychotic dose was also a significant predictor of reduced six month motivation. Results suggest that metacognition deficits and higher antipsychotic dose may be risk factors for the development of motivation deficits in schizophrenia. Implications include utilizing interventions to improve metacognition in conjunction with evaluating and possibly lowering antipsychotic dose for people struggling with motivation deficits.",
keywords = "Anticipatory pleasure, Antipsychotic medication, Metacognition, Motivation, Schizophrenia",
author = "Lauren Luther and Firmin, {Ruth L.} and Minor, {Kyle S.} and Jenifer Vohs and Benjamin Buck and Buck, {Kelly D.} and Lysaker, {Paul H.}",
year = "2016",
month = "11",
day = "30",
doi = "10.1016/j.psychres.2016.08.032",
language = "English (US)",
volume = "245",
pages = "172--178",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Metacognition deficits as a risk factor for prospective motivation deficits in schizophrenia spectrum disorders

AU - Luther, Lauren

AU - Firmin, Ruth L.

AU - Minor, Kyle S.

AU - Vohs, Jenifer

AU - Buck, Benjamin

AU - Buck, Kelly D.

AU - Lysaker, Paul H.

PY - 2016/11/30

Y1 - 2016/11/30

N2 - Although motivation deficits are key determinants of functional outcomes, little is known about factors that contribute to prospective motivation in people with schizophrenia. One candidate factor is metacognition, or the ability to form complex representations about oneself, others, and the world. This study aimed to assess whether metacognition deficits were a significant predictor of reduced prospective motivation, after controlling for the effects of baseline motivation, anticipatory pleasure, and antipsychotic medication dose. Fifty-one participants with a schizophrenia spectrum disorder completed measures of metacognition and anticipatory pleasure at baseline; participants also completed a measure of motivation at baseline and six months after the initial assessment. Baseline antipsychotic dose was obtained from medical charts. Hierarchical regression analysis revealed that lower levels of baseline metacognition significantly predicted reduced levels of motivation assessed six months later, after controlling for baseline levels of motivation, anticipatory pleasure, and antipsychotic dose. Higher baseline antipsychotic dose was also a significant predictor of reduced six month motivation. Results suggest that metacognition deficits and higher antipsychotic dose may be risk factors for the development of motivation deficits in schizophrenia. Implications include utilizing interventions to improve metacognition in conjunction with evaluating and possibly lowering antipsychotic dose for people struggling with motivation deficits.

AB - Although motivation deficits are key determinants of functional outcomes, little is known about factors that contribute to prospective motivation in people with schizophrenia. One candidate factor is metacognition, or the ability to form complex representations about oneself, others, and the world. This study aimed to assess whether metacognition deficits were a significant predictor of reduced prospective motivation, after controlling for the effects of baseline motivation, anticipatory pleasure, and antipsychotic medication dose. Fifty-one participants with a schizophrenia spectrum disorder completed measures of metacognition and anticipatory pleasure at baseline; participants also completed a measure of motivation at baseline and six months after the initial assessment. Baseline antipsychotic dose was obtained from medical charts. Hierarchical regression analysis revealed that lower levels of baseline metacognition significantly predicted reduced levels of motivation assessed six months later, after controlling for baseline levels of motivation, anticipatory pleasure, and antipsychotic dose. Higher baseline antipsychotic dose was also a significant predictor of reduced six month motivation. Results suggest that metacognition deficits and higher antipsychotic dose may be risk factors for the development of motivation deficits in schizophrenia. Implications include utilizing interventions to improve metacognition in conjunction with evaluating and possibly lowering antipsychotic dose for people struggling with motivation deficits.

KW - Anticipatory pleasure

KW - Antipsychotic medication

KW - Metacognition

KW - Motivation

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84982221277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982221277&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2016.08.032

DO - 10.1016/j.psychres.2016.08.032

M3 - Article

C2 - 27543831

AN - SCOPUS:84982221277

VL - 245

SP - 172

EP - 178

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

ER -